Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liu D
Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,
Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,
Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Grötzinger C, Exner S, Schuldt C, Du J, Sachindra S,
Keywords: receptor, targeting, imaging, prrt, peptide, angiotensin,
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,
Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,
Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,
#2827 Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine tumors (PanNETs) represent a rare and heterogeneous tumor entity. Despite advances in therapy cancer progression and resistance mechanisms are still challenging. Recent genome wide sequencing analyses in PanNETs identified a large number of mutated genes involved in epigenetic modulation.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Schmitz R
Authors: Schmitz R, Weißbach J, Kleinlein J, Schrader J, Grabowski P,
Keywords: PanNET, HDAC-Inhibition, SOCS3, lncRNA, Macrophages,